Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
There is no FDA-approved oral tirzepatide
Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs
Sedentary behaviour can counteract some of the metabolic benefits of the medication
a Phase II multicenter RCT as PL 14736 for mild-to-moderate ulcerative colitis (Pliva, completed but full results not published as a peer-reviewed paper)
This matters as a new cornerstone therapy in type 2 diabetes (T2DM), glucagon-like peptide-1 receptor agonists (GLP-1), are entering broader use, necessitating a deeper dive into how this treatment interacts, directly or indirectly, with pathways influenced by sex hormones
